title: Current stage in inflammatory bowel disease: What is next?
abstract: In recent years, the incidence of inflammatory bowel disease (IBD) has been on the rise, extending to countries where it was infrequent in the past. As a result, the gap between high and low incidence countries is decreasing. The disease, therefore, has an important economic impact on the healthcare system. Advances in recent years in pharmacogenetics and clinical pharmacology have allowed for the development of treatment strategies adjusted to the patient profile. Concurrently, new drugs aimed at inflammatory targets have been developed that may expand future treatment options. This review examines advances in the optimization of existing drug treatments and the development of novel treatment options for IBD.
authors.affiliation: Gonzalo Jesús Gómez-Gómez, Ángeles Masedo, Carmen Yela, Maria del Pilar Martínez-Montiel, Begoña Casís, Unidad de Enfermedad Inflamatoria Intestinal, Hospital 12 de Octubre, 28045 Madrid, Spain.
authors.forename: Gonzalo Jesús
authors.initials: GJ
authors.lastname: Gómez-Gómez
authors.affiliation: Gonzalo Jesús Gómez-Gómez, Ángeles Masedo, Carmen Yela, Maria del Pilar Martínez-Montiel, Begoña Casís, Unidad de Enfermedad Inflamatoria Intestinal, Hospital 12 de Octubre, 28045 Madrid, Spain.
authors.forename: Ángeles
authors.initials: Á
authors.lastname: Masedo
authors.affiliation: Gonzalo Jesús Gómez-Gómez, Ángeles Masedo, Carmen Yela, Maria del Pilar Martínez-Montiel, Begoña Casís, Unidad de Enfermedad Inflamatoria Intestinal, Hospital 12 de Octubre, 28045 Madrid, Spain.
authors.forename: Carmen
authors.initials: C
authors.lastname: Yela
authors.affiliation: Gonzalo Jesús Gómez-Gómez, Ángeles Masedo, Carmen Yela, Maria del Pilar Martínez-Montiel, Begoña Casís, Unidad de Enfermedad Inflamatoria Intestinal, Hospital 12 de Octubre, 28045 Madrid, Spain.
authors.forename: Maria del Pilar
authors.initials: Mdel P
authors.lastname: Martínez-Montiel
authors.affiliation: Gonzalo Jesús Gómez-Gómez, Ángeles Masedo, Carmen Yela, Maria del Pilar Martínez-Montiel, Begoña Casís, Unidad de Enfermedad Inflamatoria Intestinal, Hospital 12 de Octubre, 28045 Madrid, Spain.
authors.forename: Begoña
authors.initials: B
authors.lastname: Casís
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D055808:Drug Discovery / Q000639:trends*; D005544:Forecasting; D005765:Gastrointestinal Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D058990:Molecular Targeted Therapy / Q000639:trends*; D010597:Pharmacogenetics / Q000639:trends
chemical_list: D000893:Anti-Inflammatory Agents; D005765:Gastrointestinal Agents
keywords: Future directions; Inflammatory bowel disease; New drugs; Pharmacogenetic; Pharmacokinetics